Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 2,004 shares, a growth of 235.7% from the June 30th total of 597 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 10,079 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold”.

Santen Pharmaceutical Stock Up 0.2%

Shares of Santen Pharmaceutical stock opened at $11.65 on Friday. The firm has a market cap of $3.76 billion and a PE ratio of 0.10. Santen Pharmaceutical has a 12-month low of $9.22 and a 12-month high of $13.93. The company’s fifty day simple moving average is $12.48 and its two-hundred day simple moving average is $11.52.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.